<DOC>
	<DOCNO>NCT02619669</DOCNO>
	<brief_summary>Millennium develop TAK-228 , novel , highly selective , orally bioavailable adenosine 5 ' triphosphate ( ATP ) -competitive inhibitor serine/threonine kinase refer mechanistic target rapamycin ( mTOR ) . TAK-228 ( formerly INK128 MLN0128 ) target 2 distinct multiprotein complex , mTORC1 mTORC2 . TAK-228 selectively potently inhibit mTOR kinase ( IC50 = 1.1 nM ) , inhibit mTORC1/2 signaling , prevents cellular proliferation . The mTOR complex ( mTORC ) important therapeutic target generally stable ( i.e. , low tendency mutate ) key intracellular point convergence number cellular signal pathway . Inhibiting mTOR may inhibit abnormal cell proliferation , tumor angiogenesis , abnormal cellular metabolism , thus provide rationale mTOR inhibitor potential agent treatment number indication include solid tumor hematological malignancy , either monotherapy combination chemotherapeutic agent . Like rapamycin , several newly approve rapalogs ( temsirolimus everolimus ) specific allosteric inhibitor mTORC1 , partially inhibit mTORC1 signal pathway . They directly inhibit mTORC2 , show emerge target cancer research . TAK-228 develop address incomplete inhibition mTOR pathway rapalogs . Eligible subject research biopsy baseline blood urine study do within two week prior start study treatment . Subjects treat TAK-228 10 day , repeat biopsy pharmacokinetics do day 11 . The subject treat combination TAK-228 letrozole additional 110 day , undergoing resection primary tumor . Subjects treat recommended Phase II dose TAK-228 3 mg daily , dose deescalation 2 mg daily perform dose-limiting toxicity see 1/3 subject first dose level . The maximum tolerate dose cohort expand include six ten subject .</brief_summary>
	<brief_title>Neoadjuvant Run-In Study With TAK-228 Followed Letrozole/TAK-228 Women With High-Risk ER+/HER2- Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>1 . Postmenopausal woman ≥18 year age clinical stage IIV , ER positive / HER2 negative , breast cancer manage surgical resection . Patients metastatic disease diagnosis eligible clinically appropriate . The patient must baseline MRI perform standardofcare use calculate distance ( ) long dimension ( ) primary tumor ( ) . 2 . Histologic documentation breast cancer core needle incisional biopsy . 3 . Tumor size must ≥ 2 cm long dimension . 4 . Patients must high risk recurrence , define pretreatment screening period meet one follow criterion : A histologically positive nodal deposit ≥0.2 mm Histologic Grade 3 Peritumoral lymphatic vessel vascular invasion Oncotype Dx score 25 great 5 . The invasive cancer must HER2low , define IHC 01+ , FISH ratio &lt; 1.8 IHC 2+ IHC perform . 6 . The invasive cancer must estrogen receptor alpha ( ER ) positive , define ER stain IHC ≥10 % malignant tumor cell . 7 . The subject must agree 4 month ( 120 day ) neoadjuvant treatment TAK228 Letrozole , blood draw urine sample obtain , research tumor biopsy perform baseline 10 day TAK228 treatment , repeat MRI perform prior surgery ( MRI part routine clinical care ) . 8 . ECOG performance status 01 . 9 . Life expectancy 12 month longer . 10 . Adequate hematologic , hepatic , renal , glycemic function : Adequate bone marrow reserve : absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L ; platelet count ≥ 100 x 109/L ; hemoglobin ≥ 9 g/dL ; Hepatic : total bilirubin ≤ 1.5 x upper limit normal ( ULN ) , transaminase ( aspartate aminotransferase/serum glutamic oxaloacetic transaminaseAST/SGOT alanine aminotransferase/serum glutamic pyruvic transaminaseALT/SGPT ) ≤ 2.5 x ULN ; Renal : creatinine clearance ≥50 mL/min base either CockcroftGault estimate base urine collection ( 12 24 hour ) ; Metabolic : fasting serum glucose ( ≤ 130 mg/dL ) fast triglyceride ≤ 300 mg/dL ; 11 . Ability swallow oral medication maintain empty stomach state two hour prior TAK228 dose one hour follow administration . 12 . Ability give inform consent . 1 . Any serious medical psychiatric illness could , investigator 's opinion , potentially interfere completion treatment accord protocol . 2 . Any presurgical therapy breast cancer . 3 . Prior antiestrogen therapy within last 5 year . 4 . Prior treatment mTOR , AKT , PI3K inhibitor . 5 . Treatment within past two year bisphosphonate Rank ligand inhibitor . 6 . Manifestations malabsorption due prior gastrointestinal ( GI ) surgery , GI disease , unknown reason may alter absorption TAK228 . In addition , subject enteric stoma also exclude . 7 . Poorly control diabetes mellitus define HbA1c &gt; 7 % . Subjects history transient glucose intolerance due corticosteroid administration allow study inclusion/exclusion criterion meet . 8 . History follow within last 6 month prior study entry : Ischemic myocardial event , include angina require therapy artery revascularization procedure . Ischemic cerebrovascular event , include TIA artery revascularization procedure . Requirement inotropic support ( exclude digoxin ) serious ( uncontrolled ) cardiac arrhythmia ( include atrial flutter/fibrillation , ventricular fibrillation ventricular tachycardia ) . Placement pacemaker control rhythm . New York Heart Association ( NYHA ) Class III IV heart failure ( See Appendix B ) . Pulmonary embolism . 9 . Significant active cardiovascular pulmonary disease time study entry , include : Uncontrolled high blood pressure ( i.e. , systolic blood pressure &gt; 180 mm Hg , diastolic blood pressure &gt; 95 mm Hg ) Pulmonary hypertension Uncontrolled asthma O2 saturation &lt; 90 % ABG ( Arterial Blood Gas ) analysis pulse oximetry room air Significant valvular disease ; severe regurgitation stenosis image independent symptom control medical intervention , history valve replacement Medically significant ( symptomatic ) bradycardia History arrhythmia require implantable cardiac defibrillator Baseline prolongation ratecorrected QT interval ( QTc ) ( e.g. , repeated demonstration QTc interval &gt; 480 millisecond , history congenital long QT syndrome , torsade de pointes ) 10 . Treatment strong CYP3A4 CYP2C19 inhibitor and/or inducer must discontinue least 1 week administration first dose study drug . ( see Appendix C ) 11 . Initiation treatment hematopoietic growth factor , transfusion blood blood product , systemic corticosteroid ( either IV oral steroid , exclude inhaler ) within 1 week administration first dose study drug ( patient already receive erythropoietin chronic basis ≥ 4 week eligible ) . 12 . Other clinically significant comorbidities , uncontrolled pulmonary disease , active central nervous system disease , active infection , condition could compromise participation patient study . 13 . Central nervous system ( CNS ) metastasis . 14 . Known human immunodeficiency virus infection . 15 . Known hepatitis B surface antigenpositive , know suspect active hepatitis C infection . 16 . Patients receive systemic corticosteroid ( either IV oral steroid , exclude inhaler lowdose hormone replacement therapy ) within 1 week administration first dose study drug . 17 . Daily chronic use proton pump inhibitor ( PPI ) and/or take PPI within 7 day receive first dose study drug .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Neoadjuvant</keyword>
	<keyword>TAK-228 ( MLN0128 )</keyword>
	<keyword>Letrozole</keyword>
	<keyword>ER+</keyword>
	<keyword>HER2-</keyword>
</DOC>